Twelve months ago, drugmakers came roaring into 2025, fueled by a massive year of growth that peaked in the fourth quarter of ...

During a quarterly conference call, executives from Legend Biotech showed little concern for a new threat to its lone commercial product, multiple myeloma CAR-T Carvykti. | During a quarterly ...

Skyhawk Therapeutics has named Aaron Deves as chief commercial officer, securing the expertise of an executive who oversaw ...

As more drugmakers tally up their CEO compensation for 2025, yet another Big Pharma chief has collected above the $30 million threshold. | Johnson & Johnson CEO Joaquin Duato has been awarded nearly ...

What medication clears up plaque psoriasis and is recommended by most dermatologists, but also can’t be defeated or understood, has cropped up periodically throughout human history and is unaffecte | ...

About five months after U.S. Department of Health and Human Services Secretary Robert F. Kennedy Jr. | About five months after U.S. Health Secretary Robert F. Kennedy Jr. touted leucovorin as “an ...

As AstraZeneca kicks off the third year of its hockey-themed “Get Body Checked Against Cancer” campaign, the pharma has tapped two celebs known for their work both on and off the ice. | As AstraZeneca ...

Ahead of a rescheduled meeting of the Centers for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization ...

Esperion has acquired Corstasis Therapeutics and its nasal spray Enbumyst, which was approved by the FDA six months ago.

After teasing a plasma-based manufacturing expansion in the U.S. late last year, CSL is putting in the work and firming up details behind the $1.5-billion project.  | On Monday, CSL broke ground on an ...

The FDA is doubling down on its goal to increase biosimilar drug availability in the U.S. | The FDA's newest draft guidance reinforces its previous commitment to streamlining biosimilar drug ...

Amid the company’s efforts to resolve issues raised during an FDA inspection early last year, Novo Nordisk’s operating base in Plainsboro, New Jersey—already the recipient of a recent Form 483—has ...